Hostname: page-component-7b7567c8c-z4zkx Total loading time: 0 Render date: 2026-11-18T09:58:09.924Z Has data issue: false hasContentIssue false

Effectiveness and safety of caplacizumab in acquired thrombotic thrombocytopenic purpura: health technology assessment and classification according to the methodology established in Colombia

Published online by Cambridge University Press:  21 July 2023

Jahir A. Soto-Mora*
Affiliation:
Department of Evidence-Based Medicine, NeuroEconomix, Bogotá, Colombia
Lina M. Gómez-Espitia
Affiliation:
Department of Evidence-Based Medicine, NeuroEconomix, Bogotá, Colombia
Pieralessandro Lasalvia
Affiliation:
Department of Health Economics, NeuroEconomix, Bogotá, Colombia
Camilo A. Castellanos Moreno
Affiliation:
Sanofi, Bogotá, Colombia
Carol A. Casallas Vanegas
Affiliation:
Sanofi, Bogotá, Colombia
Sergio A. Londoño Gutiérrez
Affiliation:
Sanofi, Bogotá, Colombia
*
Corresponding author: Jahir A. Soto-Mora; Email: jsoto@neuroeconomix.com
Rights & Permissions [Opens in a new window]

Abstract

Objectives

Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare hematological disease whose clinical management includes caplacizumab along with plasma exchange and immunosuppression, according to international guidelines. Caplacizumab has been available in Colombia since 2022. This study seeks to determine the therapeutic classification of caplacizumab according to the methodology of the Instituto de Evaluación Tecnológica en Salud.

Methods

The classification was carried out through a deliberative process following the modified Delphi technique, with a panel of experts, made up of four hemato-oncologists, a pharmaceutical chemist, and a patient. The results of effectiveness and safety obtained through a systematic review, therapeutic thresholds (clinical significance), and degree of acceptability (willingness to use the technology) were used for the classification.

Results

Fourteen effectiveness and safety outcomes were submitted for the classification process. Caplacizumab showed clinical significance for some effectiveness outcomes, was not considered inferior in terms of safety, and displayed acceptability of use. Through consensus, the panel determined that caplacizumab plus the standard regimen is superior to the standard regimen in terms of treatment response and composite outcome, and no different for the other effectiveness and safety outcomes. Likewise, in overall terms, the panel determined that caplacizumab together with the standard regimen is superior to the standard regimen.

Conclusion

Treatment with caplacizumab together with the standard regimen was considered superior to the standard regimen for the treatment of patients with aTTP, as it showed clinically significant benefits in critical outcomes for decision making, and a safety profile no different to its comparator.

Information

Type
Assessment
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press
Figure 0

Table 1.Research question

Figure 1

Figure 1.PRISMA flow diagram.

Figure 2

Table 2.Characteristics of the included studies

Figure 3

Table 3.Results of effectiveness of included studies

Figure 4

Table 4.Therapeutic thresholds

Supplementary material: File

Soto-Mora et al. supplementary material

Soto-Mora et al. supplementary material

Download Soto-Mora et al. supplementary material(File)
File 116.2 KB